Anixa Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Anixa Biosciences has a total shareholder equity of $20.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.9M and $2.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.75m |
| Equity | US$20.69m |
| Total liabilities | US$2.22m |
| Total assets | US$22.91m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CY71's short term assets ($22.7M) exceed its short term liabilities ($2.0M).
Long Term Liabilities: CY71's short term assets ($22.7M) exceed its long term liabilities ($213.0K).
Debt to Equity History and Analysis
Debt Level: CY71 is debt free.
Reducing Debt: CY71 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CY71 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CY71 has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 7.8% each year.